Genetic deletion or antibody-mediated blockade of TREM2 in HCC models leads to enhanced IL-12 production and antigen presentation capacity, facilitating stronger T cell activation and reduced tumor growth (145, 147). Here, TREM2 is linked to hepatocellular carcinoma.